TNFalpha-Inhibition in the Treatment of Rheumatoid Arthritis

The introduction of tumor-necrosis-factor-alpha (TNFa) blocking agents is one of the milestones in the therapy of rheumatoid arthritis (RA). Edited by Larry Moreland and Paul Emery, experts in rheumatological disease, TNFa-Inhibition in the Treatment of Rheumatoid Arthritis charts the history and development of the concept of TNFa inhibition. The authors document TNFa from its discovery to its now well-documented clinical applications in the treatment of patients with RA. They compare and contrast practical management issues concerning the use of these agents both in the US and UK/Europe. The book is a practical and accessible source containing the most recent information in this field.

Jacob Boe is Professor, Department of Thoracic Medicine, Rikshospitalet, Oslo, Norway. He is Past-President of the ERS and Co-Chairman of the ERS Nebulizer Task Force.

B. Ronan O'Driscoll, BSc, MD, FRCP, is Consultant Respiratory Physician, Cardiorespiratory Medicine, Hope Hospital, Salford, UK. He is Co-Chairman of the ERS Nebulizer Task Force. He has published several papers on clinical uses of nebulized therapy.

John H. Dennis, PhD, MSc, BSc, MBIOH, DipOccHyg is a Senior Lecturer in Occupational Hygiene and Pollution Science, Department of Environmental Medicine, University of Bradford, Bradford, UK. He is Co-Chairman of the ERS Nebulizer Task Force.